Wilson B J, Torrance N, Mollison J, Wordsworth S, Gray J R, Haites N E, Grant A, Campbell M K, Miedyzbrodzka Z, Clarke A, Watson M S, Douglas A
Department of Public Health, University of Aberdeen, UK.
Health Technol Assess. 2005 Feb;9(3):iii-iv, 1-126. doi: 10.3310/hta9030.
To evaluate the effectiveness and cost-effectiveness of two complementary interventions, using familial breast cancer as a model condition. The primary care intervention consisted of providing computerised referral guidelines and related education to GPs. The nurse counsellor intervention evaluated genetic nurses as substitutes for specialist geneticists in the initial assessment and management of referred patients.
The computerised referral guidelines study was a pragmatic, cluster randomised controlled trial (RCT) with general practices randomised to intervention or control groups. The nurse counsellor intervention was tested in two concurrent RCTs conducted in separate UK health service locations, using predetermined definitions of equivalence.
The computerised referral guidelines trial took place in general practices in Scotland from November 2000 to June 2001. The nurse counsellor intervention took place in a regional genetics clinic in Scotland, and in two health authorities in Wales served by a single genetics service during 2001.
The computerised referral guidelines study involved GPs and referred patients. Both nurse counsellor intervention trials included women referred for the first time, aged 18 years or over and whose main concern was family history of breast cancer.
The software system was developed with GPs, presenting cancer genetic referral guidelines in a checklist approach. Intervention GPs were invited to postgraduate update education sessions, and both intervention and control practices received paper-based guidelines. The intervention period was November 2000 to June 2001. For the nurse counsellor trial, trial 1 ran outpatient sessions with the same appointment length as the standard service offered by geneticists, but the nurse counsellor saw new patients at the first appointment and referred back to the GP or on to a clinical geneticist according to locally developed protocol, under the supervision of a consultant geneticist. The control intervention was the current service, which comprised an initial and a follow-up appointment with a clinical geneticist. In trial 2, a nurse counsellor ran outpatient sessions with the same appointment length as the new consultant-based cancer genetics service and new patients were seen at the first appointment and referred as in trial 1. The control intervention was a new service, and comprised collection of family history by telephone followed by a consultation with a clinical assistant or a specialist registrar, supervised by a consultant. The intervention was implemented between 1998 and 2001.
In the software system trial, the primary outcome was GPs' confidence in their management of patients with concerns about family history of breast cancer. For the nurse counsellor trial, the primary outcome was patient anxiety, measured using standard scales.
In the software system trial, 57 practices (230 GPs) were randomised to the intervention group and 29 (116 GPs) to the control group. No statistically significant differences were detected in GPs' confidence or any other outcomes. Fewer than half of the intervention GPs were aware of the software, and only 22 reported using it in practice. The estimated total cost was GBP3.12 per CD-ROM distributed (2001 prices). For the two arms of the nurse counsellor trial, 289 patients (193 intervention, 96 control) and 297 patients (197 intervention and 100 control) consented, were randomised, returned a baseline questionnaire and attended the clinic for trials 1 and 2 respectively. The analysis in both cases suggested equivalence in all anxiety scores, and no statistically significant differences were detected in other outcomes in either trial. A cost-minimisation analysis suggested that the cost per counselling episode was GBP10.23 lower in intervention arm than in the control arm and GBP10.89 higher in the intervention arm than in the control arm (2001 prices) for trials 1 and 2, respectively. Taking the trials together, the costs were sensitive to the grades of doctors and the time spent in consultant supervision of the nurse counsellor, but they were only slightly affected by the grade of nurse counsellor, the selected discount rate and the lifespan of equipment.
Computer-based systems in the primary care intervention cannot be recommended for widespread use without further evaluation and testing in real practice settings. Genetic nurse counsellors may be a cost-effective alternative to assessment by doctors. This trial does not provide definitive evidence that the general policy of employing genetics nurse counsellors is sound, as it was based on only three individuals. Future evaluations of computer-based decision support systems for primary care must first address their efficacy under ideal conditions, identify barriers to the use of such systems in practice, and provide evidence of the impact of the policy of such systems in routine practice. The nurse counsellor trial should be replicated in other settings to provide reassurance of the generalisability of the intervention and other models of nurse-based assessment, such as in outreach clinics, should be developed and evaluated. The design of future evaluations of professional substitution should also address issues such as the effect of different levels of training and experience of nurse counsellors, and learning effects.
以家族性乳腺癌为范例疾病,评估两种互补干预措施的有效性和成本效益。初级保健干预措施包括为全科医生提供计算机化转诊指南及相关教育。护士咨询干预措施则评估基因护士在对转诊患者进行初始评估和管理时替代专科遗传学家的效果。
计算机化转诊指南研究是一项实用的整群随机对照试验(RCT),将全科医疗随机分为干预组或对照组。护士咨询干预措施在英国不同的医疗服务地点同时进行的两项RCT中进行测试,采用预先确定的等效性定义。
计算机化转诊指南试验于2000年11月至2001年6月在苏格兰的全科医疗中进行。护士咨询干预措施于2001年在苏格兰的一家地区遗传学诊所,以及威尔士由单一遗传学服务机构服务的两个卫生当局进行。
计算机化转诊指南研究涉及全科医生和转诊患者。两项护士咨询干预试验均纳入首次转诊的女性,年龄在18岁及以上,主要关注的是乳腺癌家族史。
该软件系统是与全科医生共同开发的,以清单形式呈现癌症基因转诊指南。邀请干预组的全科医生参加研究生更新教育课程,干预组和对照组的医疗机构均收到纸质指南。干预期为2000年11月至2001年6月。对于护士咨询试验,试验1开设门诊,预约时长与遗传学家提供的标准服务相同,但护士咨询师在首次预约时接待新患者,并根据当地制定的方案在顾问遗传学家的监督下,将患者转回给全科医生或转介给临床遗传学家。对照干预措施是现行服务,包括与临床遗传学家进行一次初始预约和一次随访预约。在试验2中,一名护士咨询师开设门诊,预约时长与新的基于顾问的癌症遗传学服务相同,新患者在首次预约时就诊,并按试验1的方式进行转诊。对照干预措施是一项新服务,包括通过电话收集家族史,随后由临床助理或专科住院医师在顾问的监督下进行咨询。干预措施于1998年至2001年实施。
在软件系统试验中,主要结局是全科医生对管理有乳腺癌家族史担忧患者的信心。对于护士咨询试验,主要结局是使用标准量表测量的患者焦虑程度。
在软件系统试验中,57家医疗机构(230名全科医生)被随机分配到干预组,29家(116名全科医生)被随机分配到对照组。在全科医生的信心或任何其他结局方面未检测到统计学上的显著差异。不到一半的干预组全科医生知晓该软件,只有22人报告在实践中使用过。估计每张分发的光盘总成本为3.12英镑(2001年价格)。对于护士咨询试验的两个组,分别有289名患者(193名干预组,96名对照组)和297名患者(197名干预组和100名对照组)同意参与、被随机分组、返回基线问卷并参加试验1和试验2的门诊。两项试验的分析均表明所有焦虑评分具有等效性,且在任何一项试验的其他结局中均未检测到统计学上的显著差异。成本最小化分析表明,试验1和试验2中,干预组每次咨询的成本分别比对照组低10.23英镑和高10.89英镑(2001年价格)。综合两项试验来看,成本对医生级别以及护士咨询师接受顾问监督所花费的时间敏感,但仅受护士咨询师级别、选定的贴现率和设备使用寿命的轻微影响。
在未经实际应用环境中的进一步评估和测试之前,不建议广泛使用初级保健干预中的基于计算机的系统。基因护士咨询师可能是医生评估的一种具有成本效益的替代方式。由于本试验仅基于三名个体,因此并未提供确凿证据表明聘用基因护士咨询师的总体政策是合理的。未来对初级保健基于计算机的决策支持系统的评估必须首先在理想条件下评估其有效性,识别在实践中使用此类系统的障碍,并提供此类系统政策在常规实践中的影响证据。护士咨询试验应在其他环境中重复进行,以确保干预措施的可推广性,并应开发和评估其他基于护士的评估模式,如在外展诊所中的应用。未来专业替代评估的设计还应解决诸如护士咨询师不同培训水平和经验的影响以及学习效应等问题。